These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35441584)

  • 1. Kratom & Stimulant Co-Addiction: A Case Series and Brief Review.
    Sablaban IM; Gautam M
    J Addict Dis; 2023; 41(2):181-184. PubMed ID: 35441584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kratom: Substance of Abuse or Therapeutic Plant?
    Gorelick DA
    Psychiatr Clin North Am; 2022 Sep; 45(3):415-430. PubMed ID: 36055730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.
    Lydecker AG; Sharma A; McCurdy CR; Avery BA; Babu KM; Boyer EW
    J Med Toxicol; 2016 Dec; 12(4):341-349. PubMed ID: 27752985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa).
    Hartley C; Bulloch M; Penzak SR
    J Clin Pharmacol; 2022 May; 62(5):577-593. PubMed ID: 34775626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kratom (Mitragyna speciosa): worldwide issues.
    Ramanathan S; McCurdy CR
    Curr Opin Psychiatry; 2020 Jul; 33(4):312-318. PubMed ID: 32452943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the possible health risks associated with the consumption of botanical preparations of
    Papadi G; Bakhiya N; Ildico Hirsch-Ernst K
    EFSA J; 2022 May; 20(Suppl 1):e200415. PubMed ID: 35634550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term buprenorphine treatment for kratom use disorder: A case series.
    Broyan VR; Brar JK; Allgaier Student T; Allgaier JT
    Subst Abus; 2022; 43(1):763-766. PubMed ID: 35112990
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute, Sublethal, and Developmental Toxicity of Kratom (
    Hughes S; van de Klashorst D; Veltri CA; Grundmann O
    Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kratom and opioid use disorder in the perioperative period: A case report on the expanding role of buprenorphine.
    Perez J
    J Opioid Manag; 2023; 19(1):91-93. PubMed ID: 36683304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kratom: A growing substance of abuse in the United States.
    Demick DS; Lee TT; Summers AT; El-Mallakh RS
    Ann Clin Psychiatry; 2020 Nov; 32(4):275-280. PubMed ID: 32722734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma.
    Hong S; Zimmerman PE; Rao V; Markwalter DW
    J Palliat Med; 2023 May; 26(5):734-736. PubMed ID: 36580544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse.
    Warner ML; Kaufman NC; Grundmann O
    Int J Legal Med; 2016 Jan; 130(1):127-38. PubMed ID: 26511390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kratom (Mitragyna speciosa): Friend or Foe?
    Sethi R; Hoang N; Ravishankar DA; McCracken M; Manzardo AM
    Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Renal Insufficiency Associated With Consumption of Hydrocodone- and Morphine-Adulterated Kratom (Mitragyna Speciosa).
    LeSaint KT; Yin S; Sharma A; Avery BA; McCurdy CR; Waksman JC
    J Emerg Med; 2022 Jul; 63(1):e28-e30. PubMed ID: 35940982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine.
    Hemby SE; McIntosh S; Leon F; Cutler SJ; McCurdy CR
    Addict Biol; 2019 Sep; 24(5):874-885. PubMed ID: 29949228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions.
    Todd DA; Kellogg JJ; Wallace ED; Khin M; Flores-Bocanegra L; Tanna RS; McIntosh S; Raja HA; Graf TN; Hemby SE; Paine MF; Oberlies NH; Cech NB
    Sci Rep; 2020 Nov; 10(1):19158. PubMed ID: 33154449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature.
    Ahmad J; Odin JA; Hayashi PH; Fontana RJ; Conjeevaram H; Avula B; Khan IA; Barnhart H; Vuppalanchi R; Navarro VJ;
    Drug Alcohol Depend; 2021 Jan; 218():108426. PubMed ID: 33257199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Kratom (Mitragyna Speciosa): a Psychoactive Plant with Opportunities and Risks].
    Gahr M
    Fortschr Neurol Psychiatr; 2023 Nov; 91(11):455-465. PubMed ID: 35613937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects.
    Prozialeck WC; Jivan JK; Andurkar SV
    J Am Osteopath Assoc; 2012 Dec; 112(12):792-9. PubMed ID: 23212430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users.
    Smith KE; Bunting AM; Walker R; Hall MT; Grundmann O; Castillo O
    J Psychoactive Drugs; 2019; 51(4):311-322. PubMed ID: 30961450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.